Effects of GBR 12909, WIN 35,428 and indatraline on cocaine self-administration and cocaine seeking in rats

被引:38
作者
Schenk, S [1 ]
机构
[1] Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA
[2] Victoria Univ Wellington, Sch Psychol, Te Kura Maatai Hinengaro, Wellington, New Zealand
关键词
cocaine self-administration; drug seeking; GBR; 12909; WIN 35,428;
D O I
10.1007/s00213-001-0972-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: It has been proposed that drugs that decrease cocaine self-administration or cocaine seeking by laboratory animals might be effective pharmacotherapies in the treatment of cocaine addiction. Previous studies have suggested that the dopamine uptake inhibitor, GBR 12909, might be such a candidate drug because it decreases cocaine self-administration. Other studies have shown that GBR 12909 elicits cocaine seeking, which might limit its utility as an anti-cocaine pharmacotherapy. Objectives: The present study sought to compare the potency of GBR 12909 in decreasing cocaine self-administration and in eliciting cocaine seeking. These findings were compared to effects produced by the cocaine analog, WIN 35,428 and the non-specific monoamine uptake inhibitor, indatraline. Methods: A within-session protocol was used to obtain the dose-effect relationship for cocaine self-administration in a single 5-6 h daily test session. Rats were pretreated with GBR 12909 (3.0-30.0 mg/kg), WIN 35,428 (0.1-1.0 mg/kg) or indatraline (0.03-1.00 mg/kg) 30 min prior to the test session. Results: GBR 12909 and WIN 35,428 decreased responding maintained by intermediate and high doses of cocaine but indatraline failed to alter the cocaine dose-effect curve. Other groups of rats demonstrated that pretreatment with all three drugs reinstated extinguished cocaine-taking behavior, although indatraline was less efficacious than either GBR 12909 or WIN 35,428. Cocaine-produced drug seeking was enhanced by pretreatment with the highest doses of GBR 12909 and WIN 35,428 but was unaffected by pretreatment with indatraline. A low dose of GBR 12909 that decreased cocaine self-administration failed to produce drug seeking but equal doses of WIN 35,428 were required to decrease cocaine self-administration and to elicit drug seeking. Conclusions: These data suggest a preferred profile of effects of GBR 12909 as an anti-cocaine pharmacotherapy. It is noted, however, that this drug might be expected to potentiate the ability of cocaine to elicit cocaine seeking following abstinence.
引用
收藏
页码:263 / 270
页数:8
相关论文
共 30 条
[1]  
Bergman J., 1990, Behav Pharmacol, V1, P355
[2]   Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers [J].
Brauer, LH ;
deWit, H .
BIOLOGICAL PSYCHIATRY, 1996, 39 (01) :26-32
[3]   High dose pimozide does not block amphetamine-induced euphoria in normal volunteers [J].
Brauer, LH ;
DeWit, H .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 56 (02) :265-272
[4]  
CAINE SB, 1994, J PHARMACOL EXP THER, V270, P209
[5]   Cocaine-predictive stimulus induces drug-seeking behavior and neural activation in limbic brain regions after multiple months of abstinence:: Reversal by D1 antagonists [J].
Ciccocioppo, R ;
Sanna, PP ;
Weiss, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (04) :1976-1981
[6]   Dopaminergic mechanisms mediating the incentive to seek cocaine and heroin following long-term withdrawal of IV drug self-administration [J].
De Vries, TJ ;
Schoffelmeer, ANM ;
Binnekade, R ;
Vanderschuren, LJMJ .
PSYCHOPHARMACOLOGY, 1999, 143 (03) :254-260
[7]  
Dworkin SI, 1998, SYNAPSE, V30, P49, DOI 10.1002/(SICI)1098-2396(199809)30:1<49::AID-SYN6>3.0.CO
[8]  
2-K
[9]   Effects of Dopamine Reuptake Inhibitors on Food- and Cocaine-Maintained Responding: I. Dependence on Unit Dose of Cocaine [J].
Glowa, John R. ;
Wojnicki, Francis H. E. ;
Matecka, Dorota ;
Bacher, John D. ;
Mansbach, Robert S. ;
Balster, Robert L. ;
Rice, Kenner C. .
EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 1995, 3 (03) :219-231
[10]  
GLOWA JR, 1995, EXP CLIN PSYCHOPHARM, V3, P231